TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05594576

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GI GENIUS™ artificial intelligence system
Description: Device used during coloscopy for detection of colonic adenoma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GI GENIUS™ artificial intelligence system
Description: Device used during coloscopy for detection of colonic adenoma

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ENDOCUFF VISION® endoscopic cap
Description: Device used during coloscopy for detection of colonic adenoma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ENDOCUFF VISION® endoscopic cap
Description: Device used during coloscopy for detection of colonic adenoma
Study: NCT06038617

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA COVID-19 Vaccine
Description: ACIP Recommended Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA COVID-19 Vaccine
Description: ACIP Recommended Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Routine Childhood Vaccinations
Description: ACIP Recommended Vaccines

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Routine Childhood Vaccinations
Description: ACIP Recommended Vaccines
Study: NCT05724472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rVSV∆G-SEBOV-GP Vaccine or Placebo
Description: rVSV∆G-SEBOV-GP Vaccine or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rVSV∆G-SEBOV-GP Vaccine or Placebo
Description: rVSV∆G-SEBOV-GP Vaccine or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rVSV∆G-SEBOV-GP Vaccine or Placebo
Description: rVSV∆G-SEBOV-GP Vaccine or Placebo
Study: NCT05936411

Intervention type: DEVICE
Group type: OTHER
Intervention: Siemens Quadra PET/CT and [18F]FDG
Description: The Siemens Quadra PET/CT, a clinically approved imaging device, is utilized in conjunction with the radiopharmaceutical tracer \[18F\]FDG in this study. The device allows for the acquisition of emission data across an extended axial field of view (axFOV) of 106 cm, covering an imaging range from the head to the thighs. The device's capabilities are leveraged to perform quantitative functional examinations of an extended axFOV. Subjects are scanned twice within a month for reproducibility standards. Each time, they are injected with 100MBq \[18F\]FDG and examined for 60 minutes in a dynamic scan. The tracer is used to build an atlas of normative glycolytic activities for most organs, excluding the brain. The glycolytic activities are measured as organ-based standardized uptake values. An ultra-low-dose CT scan is acquired to estimate mandatory attenuation correction factors.

Intervention type: DEVICE
Group type: OTHER
Intervention: Apple i-Watch
Description: The Apple i-Watch, a wearable smart device, is used to continuously monitor physiological signals from the subjects. These signals include heart rate, steps and distance, calories burned, sleep tracking, blood oxygen saturation (SpO2), electrocardiogram (ECG), and workout tracking. Subjects are required to wear the Apple i-Watch for three months prior to the first PET scan and up to three months after the second PET scan. The data collected from the Apple i-Watch is paired with the FDG-PET image readouts to identify relationships between lifestyle and glucose uptakes during the scan.
Study: NCT06664762

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Left lateral position intervention
Description: Patients will be randomized and asigned to start and remain in left lateral position during the colonoscopy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supine position intervention
Description: Patients will be randomized and asigned to start and remain in supine position during the colonoscopy
Study: NCT04920032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: 6 cycles for a 2-week regimen (infusional 5FU based) and up to 4 cycles for a 3-week regimen (oral capecitabine based) after randomization

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Signatera MRD ctDNA Assay
Description: To be performed within 6-8 weeks of Cycle 1 Day 1. A Mid-treatment ctDNA is to be completed within 6 - 8 weeks of starting treatment. ctDNA is to also be completed within four weeks after completion of study treatment (+/- two weeks)
Study: NCT05241847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PeLTQL delivery via electronic means
Description: Delivery of PeLTQL scoring information to clinicians via electronic means.
Study: NCT06604871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin Pump with Continuous Glucose Monitoring
Description: MiniMed™ 780G insulin pump in combination with the DS5 CGM
Study: NCT06612762

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: The daily ingestion of capsules containing naringenin
Description: Following surgical intervention, patients will be administered two capsules (equivalent to 500 mg) daily for a period of 14 days. Subsequently, patients will ingest the maintenance dose of 250 mg per day until the 90th day post-surgery.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The daily ingestion of capsules containing placebo
Study: NCT06675994

Intervention type: DRUG
Intervention: PCSK9 Antibody, PCSK9 Enzyme
Description: In-vitro demonstration of the direct effect if the PCSK9 enzyme on platelets. The study will use commercially available recombinant PCSK9 enzyme to promote platelet activity and the PCSK9 antibody to inhibit activity. In each patient, platelet function testing will occur in the absence of PCSK9 enzyme, after the addition of PCSK9 enzyme, and after the addition of both PCSK9 enzyme and antibody reagent to the blood sample prior to testing.

Intervention type: DRUG
Intervention: PCSK9 Antibody, PCSK9 Enzyme
Description: In-vitro demonstration of the direct effect if the PCSK9 enzyme on platelets. The study will use commercially available recombinant PCSK9 enzyme to promote platelet activity and the PCSK9 antibody to inhibit activity. In each patient, platelet function testing will occur in the absence of PCSK9 enzyme, after the addition of PCSK9 enzyme, and after the addition of both PCSK9 enzyme and antibody reagent to the blood sample prior to testing.
Study: NCT06676553

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation alone, re-denervation to main and/or branch renal artery
Description: Re-denervation according to the site where renal artery stimulation can induce systolic blood pressure rise of \>= 20 mmHg. Main renal artery denervation if proximal main renal artery stimulation positive, while branch renal artery denervation if distal main renal artery stimulation positive.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Radiofrequency ablation alone, no further renal denervation
Description: No further renal denervation after standard renal denervation even renal artery stimulation-induced systolic blood pressure rise \>= 20 mmHg
Study: NCT06677099

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chest physiotherapy
Description: Two sessions of CPT (morning and afternoon, 20 minutes each) were conducted. The CPT session consisted of modified postural drainage, assisted cough technique , positive expiratory pressure and chest percussion, vibration. The appointed therapist performed pulmonary auscultation and thoracic palpation to assess the status of pulmonary ventilation and secretion retention, and whether the patient's cough ability can complete effective airway clearance. Individualized program was formed according to the assessment, internal guidelines, the patient's tolerance, education level, and patient's preference prior to the randomization. All CPT sessions were performed by the same physiotherapist to avoid potential bias.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EIT-guided chest physiotherapy
Description: EIT-guided modified postural drainage combined with vibrations and chest percussion: tidal variation images in EIT reveals heterogeneously ventilated regions. Physiotherapist identified such regions at the bedside and instructed the patient to take the appropriate drainage position, so that the poorly ventilated regions became gravity non-dependent regions. Subsequently, the physiotherapist put her hands on the poorly ventilated area with a vibratory force. A compressive pressure was produced by the therapist's arms.
Study: NCT06676917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan
Description: Trophoblast cell surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) consisting of a humanized anti-TROP2 monoclonal antibody (MAAP-9001a), a GGFG tetra-peptide linker, and a Topo I inhibitor (MAAA-1181a, derived from exatecan). Upon binding to TROP2 on the cell surface, Dato-DXd internalizes into the cells and releases MAAA-1181a in the cytoplasm which inhibits cell replication and promotes cell apoptosis.
Study: NCT06676930

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy With Computer-Aided Detection
Description: Use of Computer-Aided Detection During Colonoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy without Computer-Aided Detection
Description: Colonoscopy without Computer-Aided Detection (AI)
Study: NCT06677216

Intervention type: PROCEDURE
Intervention: Botulinum Toxin, Type A
Description: All participants will receive a solution of BTX-A (Xeomin, Merz Pharma GmbH, Frankfurt am Main, Germany) in the masseter and temporalis muscles (total of 100 units reconstituted with 4cc unpreserved 0.9% sodium chloride). The injection will be provided by the same maxillofacial surgeon. The participants are asked to clench their teeth to determine the site of the most intense muscle activity in the masseter and temporal muscles with palpation. Intramuscular BTX-A injections are administered on both sides at the location of the most intense muscle activity of the masseter (80 units) and temporalis (20 units).
Study: NCT06122727

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total knee arthroplasty
Description: In detail, in the STANDARD group, patients will undergo a primary TKR by implanting a prosthetic model of the same standard design for all using the usual surgical technique and instrumentation (based on the use of guide intramedullary of femur and extramedullary of tibia); in the PERSONALIZED group, patients will undergo a primary TKA by implanting a prosthetic model (YourKnee, Rejoint) with design based specifically on each patient's actual knee morphology and using PSI surgical technique and instrumentation. In both groups, the approach of the basic prosthetic design base will be of the Cruciate-Retaining (CR) type with congruent polyethylene (PE), with standard and customized for the STANDARD and CUSTOM group, respectively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty
Description: In detail, in the STANDARD group, patients will undergo a primary TKR by implanting a prosthetic model of the same standard design for all using the usual surgical technique and instrumentation (based on the use of guide intramedullary of femur and extramedullary of tibia); in the PERSONALIZED group, patients will undergo a primary TKA by implanting a prosthetic model (YourKnee, Rejoint) with design based specifically on each patient's actual knee morphology and using PSI surgical technique and instrumentation. In both groups, the approach of the basic prosthetic design base will be of the Cruciate-Retaining (CR) type with congruent polyethylene (PE), with standard and customized for the STANDARD and CUSTOM group, respectively.
Study: NCT06676826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrabony defects will be filled with a volume-stable collagen matrix (VCMX)
Description: Infrabony defects will be filled with a volume-stable collagen matrix

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infrabony defects will be filled treated with a deproteinized bovine bone mineral with 10% collagen
Description: Infrabony defects will be filled with with a deproteinized bovine bone mineral with 10% collagen
Study: NCT06677450

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuoroscience education
Description: Pain neurosicence education will be applied 1 day / 6 weeks at the beginning of one of the weekly exercise sessions in addition to the exercise program. The educations will include the definition and general characteristics of pain, pain physiology, peripheral neuropathic pain, the role of the brain in pain perception, tissue healing, peripheral and central sensitization, the effects of emotional, psychological and social factors on the pain process and pain coping strategies.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise program will be applied 2 days/week for 6 weeks and will consist of 3-phase stretching and motor control/progressive resistance exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise program will be applied 2 days/week for 6 weeks and will consist of 3-phase stretching and motor control/progressive resistance exercises.
Study: NCT06676202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Relaxation Exercises
Description: It combines the contraction and relaxation of large muscle groups such as the face, arms, legs, neck and back with deep breathing exercises. Before applying progressive relaxation exercises, the environment should be quiet, dimly lit, a comfortable chair or armchair should be sat or lying down, and clothing should be loose and comfortable, and it is recommended to apply it one hour after eating. In the application of progressive relaxation exercises, it is first asked to breathe regularly. After our breathing rhythm is regulated, the hands, arm muscles, shoulder and neck muscles, chest, abdominal and hip muscles, legs, feet and facial muscles are contracted with a 5-7 second breathing exercise and relaxed during exhalation. This is repeated with 4-5 breathing exercises for each muscle and the exercise is ended when the eyelids are opened.
Study: NCT06285097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07820435
Description: immune agonist
Study: NCT05273463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classroom-Based Intervention
Description: Virtual 30-minute course with an Orthopedic nurse about what to expect before, during, and after your surgery
Study: NCT05434858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-energy CT (DECT) and ultrasound
Description: DECT and ultrasound will be performed to clarify the pathological mechanisms responsible for the transition from asymptomatic crystalline deposition to gout, and the mechanisms involved in the transition from hyperuricemia to de novo crystalline deposition.
Study: NCT04986852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olinvacimab
Description: Treatment with Olinvacimab and Pembrolizumab is to be continued until disease progression, the development of unacceptable toxicity or patient's withdrawal of consent. Maximum duration of treatment will be 35 cycles (approximately 2 years).
Study: NCT05531058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI-driven Vaccine Communicator
Description: The intervention will include five modules web-based psychoeducation programme (two module sessions weekly, each module lasts for 15-20 minutes) and interact with an MI communication skills-based AI, digital assistant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-learning of COVID-19 vaccine knowledge
Description: Participants in the control group will be given HK government websites in COVID-19 vaccine and invite to join the online examination in relation to Covid-19 vaccine knowledge (using multiple choices questions similar to the intervention group), and this is to ensure that participants from the control group also use time to search relevant information of covid-19 vaccines, also this is to control the time effects.
Study: NCT06285097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07820435
Description: immune agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07820435
Description: immune agonist
Study: NCT04969497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: M207 3.8 mg MiniMac
Description: Treatment A: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MiniMac coater and packaged in foil cups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: M207 3.8 mg MiniMac
Description: Treatment A: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MiniMac coater and packaged in foil cups
Study: NCT06085937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Patients will receive 0.2mg/kg of IV ketamine
Study: NCT04799236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: Miltefosine
Description: Miltefosine 50 mg pill will be administered po every 8 hours with food, during 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: Pentavalent Antimony
Description: will be administered by IV infusion diluted in 150 ml of DWD5% over 20 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 3: Liposomal amphotericin B
Description: 3 amps (150 mg) will be administered by IV infusion iver 2 hours every other day for a total of 15 doses.
Study: NCT05923476

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lithium
Description: Placebo + ECT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Placebo + ECT
Study: NCT06053216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indirect calorimetry
Description: Weekly indirect calorimetry measurements using the Q-NRG+ device will be used to guide energy delivery up to day 28 of hospital admission.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Indirect calorimetry (Standard care nutrition arm)
Description: Weekly indirect calorimetry measurements using the Q-NRG+ device will be conducted up to day 28 of hospital admission. In the standard care nutrition arm, clinicians will be blinded to indirect calorimetry measurements.
Study: NCT05414617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-articular single injection
Description: Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment.~The injection will be performed at Day 1.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-articular three injections
Description: Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment.~The injections will be performed at Days 1, 8 and 15.
Study: NCT02085876

Intervention type: OTHER
Intervention: 2 additional MRI sequences

Intervention type: OTHER
Intervention: An additional blood sample
Study: NCT04076150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve (TAV) Implantation With The Optimum TAV System
Description: Treating patients with severe symptomatic aortic stenosis via transcatheter aortic valve implantation by implanting the Optimum TAV inside the native diseased valve via a the Precision Catheter. The Optimum TAV and Precision Catheter together are the Optimum TAV System.
Study: NCT04922619

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tonotopy based fitting then default fitting
Description: Cochlear implant with default fitting then tonotopy based fitting
Study: NCT06285097

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/L2
Study: NCT04922619

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tonotopy based fitting then default fitting
Description: Cochlear implant with default fitting then tonotopy based fitting

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: default fitting then tonotopy based fitting
Description: Cochlear implant with tonotopy based fitting then default fitting

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: default fitting then tonotopy based fitting
Description: Cochlear implant with tonotopy based fitting then default fitting
Study: NCT06063252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NISMA
Description: The intervention NISMA is a nine-month intervention and consisted of four individual sessions and two group sessions. The theoretical frame is Social Cognitive Theory, along with Acceptance and Commitment Therapy (ACT), to support the enhancement of self-efficacy. It involves four individual face-to-face sessions with a nurse and two group sessions (5-7 patients) with a nurse, an occupational therapist (OT), and a physiotherapist (PT), with the nurse being the facilitator. Every session has a specific topic and, in every session, a person-centered approach was used to address current problems and secure relevance.~Participants in the control group receive usual care, and the intervention group receives both usual care supplemented with the intervention.